Cardiovascular Journal of Africa: Vol 29 No 2 (March/April 2018)

67 / 84

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 2, March/April 2018 AFRICA 129
Mitochondrial DNA stress primes the antiviral innate immune response.
Nature 2015; 520(7548): 553–537. doi:10.1038/nature14156.
36. Yu E, Calvert P, Mercer J, Harrison J, Baker L, Figg N, et al.
Mitochondrial DNA damage can promote atherosclerosis indepen-
dently of reactive oxygen species through effects on smooth muscle
cells and monocytes and correlates with higher-risk plaques in humans.
Circulation 2013; 128: 702–712. doi: 10.1161/circulationaha.113.002271.
37. Mercer JR. Mitochondrial bioenergetics and therapeutic intervention in
cardiovascular disease. Pharmacol Therapeut 2014; 141(1):13–20. http://
38. Yu EP, Bennett MR. Mitochondrial DNA damage and atheroscle-
rosis. Trends Endocrin Metab 2014; 25(9): 481–487. .
org/10.1016/j.tem.2014.06.008.
39. Lightowlers RN, Taylor RW, Turnbull DM. Mutations causing mito-
chondrial disease: What is new and what challenges remain? Science
2015; 349(6255): 1494–1499. doi: 10.1126/science.aac7516.
40. DiMauro S, Schon E. Mitochondrial DNA mutations in human disease.
Am J Med Genet 2001; 106:18–26. doi: 10.1002/ajmg.1392.
41. McFarland R, Elson JL, Taylor RW, Howell N, Turnbull DM. Assigning
pathogenicity to mitochondrial tRNA mutations: when ‘definitely
maybe’ is not good enough. Trends Genet 2004; 20: 591–596. doi:
10.1016/j.tig.2004.09.014.
42. Montoya J, López-Gallardo E, Díez-Sánchez C, López-Pérez MJ,
Ruiz-Pesini E. 20 years of human mtDNA pathologic point mutations:
Carefully reading the pathogenicity criteria. Biochim Biophys Acta 2009;
1787: 476–483. doi:10.1016/j.bbabio.2008.09.003.
43. Yarham JW, Al-Dosary M, Blakely EL, Alston CL, Taylor RW, Elson
JL, et al. A comparative analysis approach to determining the patho-
genicity of mitochondrial tRNA mutations. Hum Mutat 2011; 32(11):
1319–1325. doi: 10.1002/humu.21575.
44. Mitchell AL, Elson JL, Howell N, Taylor RW, Turnbull DM. Sequence
variation in mitochondrial complex I genes: mutation or polymorphism?
J Med Genet 2006; 43: 175–179. doi: 10.1136/jmg.2005.032474.
45. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat J, Letellier T.
Mitochondrial threshold effects. Biochem J 2003; 370(Pt 3): 751–762.
doi: 10.1042/bj20021594.
46. Faustin B, Rossignol R, Rocher C, Bénard G, Malgat M, Letellier T.
Mobilization of adenine nucleotide translocators as molecular bases of
the biochemical threshold effect observed in mitochondrial diseases. J
Biol Chem 2004; 279(19): 20411–20421. doi 10.1074/jbc.m314259200.
47. Picard M, Hirano M. Disentangling (epi)genetic and environmental
contributions to the mitochondrial 3243A>G mutation phenotype:
Phenotypic destiny in mitochondrial disease? J Am Med Assoc Neurol
2016; 73(8): 923–925. doi: 10.1001/jamaneurol.2016.1676.
48. Kirches E. LHON: Mitochondrial mutations and more. Curr Genomics
2011; 12: 44–54. doi: 10.2174/138920211794520150.
49. Kirkman M, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis
K, De Coo I, et al. Gene–environment interactions in Leber hereditary
optic neuropathy. Brain 2009; 132(Pt 9): 2317–2326. doi: 10.1093/brain/
awp158.
50. Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, et
al. Clinical expression of Leber hereditary optic neuropathy is affected
by the mitochondrial DNA-haplogroup background. Am J Hum Genet
2007; 81(2): 228–233.
51. Ji Y, Zhang A, Jia X, Zhang Y, Xiao X, Li S, et al. Mitochondrial DNA
haplogroups M7b1’2 and M8a affect clinical expression of Leber heredi-
tary optic neuropathy in Chinese families with m.11778G>A mutation.
Am J Hum Genet 2008; 83(6): 760–768. doi: 10.1016/j.ajhg.2008.11.002.
52. Ong S-B, Kalkhoran S, Cabrera-Fuentes H, HausenloyD.Mitochondrial
fusion and fission proteins as novel therapeutic targets for treating cardi-
ovascular disease. Eur J Pharmacol 2015; 763:104–114. .
org/10.1016/j.ejphar.2015.04.056.
53. Finsterer J, Kothari S. Cardiac manifestations of primary mitochondrial
disorders. Int J Cardiol 2014; 177: 754–763.
ijcard.2014.11.014.
54. Yaplito-Lee J, Weintraub R, Jamsen K, Chow C, Thorburn D, Boneh A.
Cardiac manifestations in oxidative phosphorylation disorders of child-
hood. J Pediatr 2007; 150(4): 407–411. doi:
jpeds.2006.12.047.
55. Limongelli G, Masarone D, D’Alessandro R, Elliott PM. Mitochondrial
diseases and the heart: an overview of molecular basis, diagnosis, treat-
ment and clinical course. Future Cardiol 2012; 8(1):71–88. doi: 10.2217/
fca.11.79.
56. Villar P, Bretón B, García-Pavía P, González-Páramos C, Blázquez A,
Gómez-Bueno M, et al. Cardiac dysfunction in mitochondrial disease.
Circ J 2013; 77(11): 2799–2806. doi: 10.1253 -13-0557.
57. Yajima N, Yazaki Y, Yoshida K, Sano K, Takahashi W, Sasaki Y, et
al. A case of mitochondrial cardiomyopathy with pericardial effusion
evaluated by 99mTc-MIBI myocardial scintigraphy. J Nucl Cardiol 2009;
16(6): 989–994. doi:10.1007/s12350-009-9149-y.
58. Malfatti E, Laforêt P, Jardel C, Stojkovic T, Behin A, Eymard B, et al .
High risk of severe cardiac adverse events in patients with mitochondrial
m. 3243A> G mutation. Neurology 2013; 80(1): 100–105. doi: http:/​/​dx.​
doi.​org/​10.​1212/​WNL.​0b013e31827b1a2f .
59. Finsterer J, Stöllberger C, Kopsa W. Noncompaction on cardiac MRI in
a patient with nail-patella syndrome and mitochondriopathy. Cardiology
2003; 100(1): 48–49. doi:10.1159/000072393.
60. Inamori M, Ishigami T, Takahashi N, Hibi K, Ashino K, Sumita S,
et al. A case of mitochondrial cardiomyopathy with heart failure, sick
sinus syndrome and diabetes mellitus: mitochondrial DNA adenine-to-
guanine transition at 3243 of mitochondrial tRNA (LEU)(UUR) gene.
J Cardiol 1997; 30(6): 341–347. PMID: 9436076.
61. Majamaa-Voltti K, Peuhkurinen K, Kortelainen ML, Hassinen IE,
Majamaa K. Cardiac abnormalities in patients with mitochondrial
DNA mutation 3243A> G. BMC Cardiovasc Disord 2002; 2(1): 1. doi:
10.1186/1471-2261-2-12.
62. Hollingsworth KG, Gorman GS, Trenell MI, McFarland R, Taylor RW,
Turnbull DM, et al. Cardiomyopathy is common in patients with the
mitochondrial DNA m. 3243A> G mutation and correlates with muta-
tion load. Neuromusc Disord 2012; 22(7): 592–596. doi: .
org/10.1016/j.nmd.2012.03.001.
63. Mima A, Shiota F, Matsubara T, Iehara N, Akagi T, Abe H, et al. An
autopsy case of mitochondrial myopathy, encephalopathy, lactic acido-
sis, and stroke-like episodes (MELAS) with intestinal bleeding in chronic
renal failure. Renal Fail 2011; 33(6): 622–625.
0886022X.2011.585730.
64. Vydt TC, de Coo RF, Soliman OI, Folkert J, van Geuns RJ, Vletter
WB, et al. Cardiac involvement in adults with m. 3243A> G MELAS
gene mutation. Am J Cardiol 2007; 99(2): 264–269. .
org/10.1016/j.amjcard.2006.07.089.
65. Hung PC, Wang HS, Chung HT, Hwang MS, Ro LS. Pulmonary
hypertension in a child with mitochondrial A3243G point mutation.
Brain Develop 2012; 34(10): 866–868.
dev.2012.02.011.
66. Liu CH, Chang CH, Kuo HC, Ro LS, Liou CW, Wei YH, et al.
Prognosis of symptomatic patients with the A3243G mutation of mito-
chondrial DNA. J Formosan Med Assoc 2012; 111(9): 489–494. http://
67. Sproule DM, Dyme J, Coku J, de Vinck D, Rosenzweig E, Chung WK,
et al. Pulmonary artery hypertension in a child with MELAS due to